Clearbridge Biomedics

Biolidics Limited, which previously operated under the name Clearbridge Biomedics, is a Singapore-based medical technology company focused on the oncology sector. The company originated as a spin-off from the National University of Singapore (NUS) and was the inaugural incubatee of Clearbridge Accelerator, an entity supported by Singapore's National Research Foundation.

The company's core business revolves around the development and commercialization of advanced cell enrichment systems for cancer diagnostics and monitoring. Its primary offering is the ClearCell® FX1 System, a fully automated, CE-IVD certified medical device. This system utilizes a proprietary microfluidic technology to effectively isolate and enrich circulating tumor cells (CTCs) from a standard blood sample. This process, commonly referred to as a liquid biopsy, presents a minimally invasive alternative to traditional surgical tissue biopsies. The ability to detect and analyze CTCs offers significant applications across the entire cancer care continuum, including initial diagnosis, prognosis assessment, tailoring personalized treatments, and ongoing monitoring of treatment effectiveness.

Biolidics generates revenue through the sale and installation of its ClearCell® FX1 Systems. The business model targets a clientele of academic and research institutions, hospitals, and clinical laboratories. Geographically, the company has established a footprint with installations in key markets across Asia, the United States, and several European Union countries, positioning itself as a key equipment provider in the growing field of liquid biopsy and personalized medicine.

Keywords: liquid biopsy, cancer diagnostics, medical technology, circulating tumor cells, oncology, microfluidics, cell enrichment, diagnostic equipment, personalized medicine, non-invasive.